Agenus | AGEN - Current Assets


Agenus reported $78.81M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Agenus USD 78.81M 16.47M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Celldex Therapeutics USD 724.93M 265.71M Jun/2026
CSL USD 11.85B 1000K Dec/2025
Eli Lilly USD 64.67B 9.84B Jun/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Intrexon USD 23.72M 45.04M Jun/2024
J&J USD 59.77B 601M Jun/2026
Jiangsu Hengrui CNY 49.61B 2.44B Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Merck EUR 13.77B 393M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Northwest Biotherapeutics USD 6.2M 996K Mar/2026
Novartis USD 27.35B 744M Jun/2026
Novavax USD 771.1M 79.72M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Veracyte USD 574.78M 52.6M Jun/2026